Market

Market crash slumps biotech as investors yank $1.2B from funds

After soaring 11% on the highs of JPM hype and mega-sized mergers and acquisitions, the Nasdaq Biotech Index is tumbling in February.

That rapid downshift is tied to investors pulling $1.2 billion out of health care and biotech funds last week, bringing the NBI down 8.2% since the start of the month.

The good news (or perhaps bad news, depending on your perspective) is biotech is not alone in this sudden slip. The Nasdaq Composite, which is heavily weighted with the stocks of tech companies, is showing a near identical trend. The index is down 8.24% since the start of the month.

And earlier this week, the Dow suffered its worst fall in six years, losing over 4% in a single day, triggering a sell-off around the world. The S&P 500 tanked 100 points Thursday by close, down 3.75%.

Randy Frederick

“We’re now in what we call full correction territory,” Randy Frederick, vice president of trading and derivatives for Charles Schwab, told ABC News.

The fall may not be directly tied to the industry, but it’s a correction many in biotech have been calling for. The collective giddiness over tax reform, a hot IPO season, and flush biotech VC began to send warning signals to prudent investors.

“You keep your hand on the eject button,” an unnamed hedge fund manager told STAT’s Damian Garde in January.

And biotech investor Brad Loncar, responding to questions about Armo, Menlo, and Solid’s IPO performance, wrote me this in an email last month: “To be honest, I think it is all too frothy.”

As much as we’d love to give you a crystal ball for what’s ahead, it’s impossible to predict.

“I’m not ready to call the bottom,” Frederick said. “I always tell people it’s best to wait until you get an ease back in volatility and you get two good, solid days. We haven’t had that.”


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->